Takeda Financial Statements From 2010 to 2024

TAK Stock  USD 13.23  0.15  1.12%   
Takeda Pharmaceutical financial statements provide useful quarterly and yearly information to potential Takeda Pharmaceutical Co investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Takeda Pharmaceutical financial statements helps investors assess Takeda Pharmaceutical's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Takeda Pharmaceutical's valuation are summarized below:
Gross Profit
2.4 T
Profit Margin
0.0428
Market Capitalization
42 B
Enterprise Value Revenue
0.017
Revenue
4.2 T
There are currently one hundred twenty fundamental trend indicators for Takeda Pharmaceutical Co that can be evaluated and compared over time across competition. We recommend to double-check Takeda Pharmaceutical's current fundamental drivers against the all of the trends between 2010 and 2024. Market Cap is expected to rise to about 4.7 T this year, although Enterprise Value will most likely fall to about 3.8 T.

Takeda Pharmaceutical Total Revenue

4.86 Trillion

Check Takeda Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Takeda main balance sheet or income statement drivers, such as Depreciation And Amortization of 867.8 B, Interest Expense of 204.9 B or Selling General Administrative of 775 B, as well as many exotic indicators such as Price To Sales Ratio of 0.92, Dividend Yield of 0.0775 or PTB Ratio of 0.59. Takeda financial statements analysis is a perfect complement when working with Takeda Pharmaceutical Valuation or Volatility modules.
  
This module can also supplement Takeda Pharmaceutical's financial leverage analysis and stock options assessment as well as various Takeda Pharmaceutical Technical models . Check out the analysis of Takeda Pharmaceutical Correlation against competitors.

Takeda Pharmaceutical Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets16.9 T16.1 T8.7 T
Slightly volatile
Common Stock Shares Outstanding1.3 B1.4 B1.6 B
Slightly volatile
Short and Long Term Debt Total5.3 TT2.7 T
Slightly volatile
Other Current Liabilities1.8 T1.7 T726.1 B
Slightly volatile
Total Current LiabilitiesT2.9 T1.6 T
Slightly volatile
Total Stockholder Equity7.7 T7.3 T3.9 T
Slightly volatile
Property Plant And Equipment NetT1.9 TT
Slightly volatile
Current Deferred Revenue744.4 B709 B406.3 B
Slightly volatile
Retained Earnings1.4 T1.4 T1.6 T
Slightly volatile
Accounts Payable783.9 B746.6 B327.1 B
Slightly volatile
Cash597.2 B480.2 B568.6 B
Slightly volatile
Non Current Assets Total14 T13.3 T6.7 T
Slightly volatile
Cash And Short Term Investments737.6 B498.3 B643.3 B
Pretty Stable
Net Receivables540 B783.9 B581.9 B
Slightly volatile
Common Stock Total EquityT1.9 T876.6 B
Slightly volatile
Short Term Investments17.2 B18.2 B66.5 B
Slightly volatile
Liabilities And Stockholders Equity16.9 T16.1 T8.7 T
Slightly volatile
Non Current Liabilities Total6.2 T5.9 T3.2 T
Slightly volatile
Inventory1.2 T1.1 T560 B
Slightly volatile
Other Current Assets194.2 B185 B101 B
Slightly volatile
Total Liabilities9.2 T8.7 T4.8 T
Slightly volatile
Property Plant And Equipment Gross3.3 T3.1 T1.3 T
Slightly volatile
Total Current AssetsT2.8 T1.9 T
Slightly volatile
Short Term Debt410.1 B390.5 B281.5 B
Slightly volatile
Common StockT1.9 T879 B
Slightly volatile
Good Will5.8 T5.5 T2.6 T
Slightly volatile
Intangible Assets5.2 T4.9 T2.6 T
Slightly volatile
Other Liabilities713.1 B625.7 B479.2 B
Slightly volatile
Property Plant Equipment1.1 T1.9 T809.2 B
Slightly volatile
Cash And Equivalents382 B613.6 B339.8 B
Slightly volatile
Net Invested Capital10 T12.3 T6.5 T
Slightly volatile
Capital Stock1.8 T1.9 T1.7 T
Slightly volatile

Takeda Pharmaceutical Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization867.8 B826.5 B399.6 B
Slightly volatile
Interest Expense204.9 B195.2 B90.4 B
Slightly volatile
Selling General Administrative775 B1.1 T758.1 B
Slightly volatile
Total Revenue4.9 T4.6 T2.6 T
Slightly volatile
Gross Profit3.4 T3.2 T1.8 T
Slightly volatile
Other Operating Expenses4.3 T4.1 T2.3 T
Slightly volatile
EBITDA1.5 T1.4 T673.4 B
Slightly volatile
Cost Of Revenue1.5 T1.4 T796.1 B
Slightly volatile
Total Operating Expenses2.8 T2.6 T1.5 T
Slightly volatile
Selling And Marketing Expenses129.8 B201.8 B169.7 B
Pretty Stable
Research Development460.2 B728.3 B426.4 B
Slightly volatile
Interest Income41.1 B72.3 B29.9 B
Slightly volatile
Reconciled Depreciation521.7 B764.1 B360.4 B
Slightly volatile

Takeda Pharmaceutical Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow625.5 B764.7 B599.5 B
Slightly volatile
Depreciation802.3 B764.1 B379.6 B
Slightly volatile
Dividends Paid337.4 B321.3 B196.8 B
Slightly volatile
Capital Expenditures765.2 B728.7 B240.5 B
Slightly volatile
Total Cash From Operating Activities1.2 T1.1 T547.5 B
Slightly volatile
End Period Cash Flow637 B480.2 B562.3 B
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.920.971.9194
Slightly volatile
Dividend Yield0.07750.07380.0558
Slightly volatile
PTB Ratio0.590.621.4916
Slightly volatile
Days Sales Outstanding11571.0598.471
Slightly volatile
Book Value Per Share3.9 K3.7 K2.3 K
Slightly volatile
Invested Capital0.650.620.5697
Slightly volatile
Operating Cash Flow Per Share595567326
Slightly volatile
PB Ratio0.590.621.4916
Slightly volatile
EV To Sales3.22.072.7172
Slightly volatile
Inventory Turnover2.491.451.9157
Slightly volatile
Days Of Inventory On Hand150260224
Slightly volatile
Payables Turnover3.752.22.9803
Slightly volatile
Sales General And Administrative To Revenue0.370.470.4971
Very volatile
Research And Ddevelopement To Revenue0.190.180.1814
Slightly volatile
Cash Per Share606410417
Slightly volatile
POCF Ratio3.814.0121.3831
Slightly volatile
Days Payables Outstanding105171132
Slightly volatile
EV To Operating Cash Flow6.356.6824.8988
Pretty Stable
Intangibles To Total Assets0.610.580.498
Slightly volatile
Current Ratio1.061.111.5373
Slightly volatile
Receivables Turnover2.95.323.8954
Slightly volatile
Graham Number4.1 K3.9 K2.3 K
Slightly volatile
Shareholders Equity Per Share3.9 K3.7 K2.3 K
Slightly volatile
Debt To Equity0.650.620.5697
Slightly volatile
Revenue Per Share2.5 K2.3 K1.5 K
Slightly volatile
Interest Debt Per Share2.8 K2.6 K1.6 K
Slightly volatile
Debt To Assets0.30.280.2509
Slightly volatile
Enterprise Value Over EBITDA8.575.412.1559
Slightly volatile
Short Term Coverage Ratios2.462.591.4 K
Very volatile
Operating Cycle234316319
Pretty Stable
Price Book Value Ratio0.590.621.4916
Slightly volatile
Days Of Payables Outstanding105171132
Slightly volatile
Price To Operating Cash Flows Ratio3.814.0121.3831
Slightly volatile
Company Equity Multiplier1.421.982.0695
Slightly volatile
Long Term Debt To Capitalization0.370.350.3036
Slightly volatile
Total Debt To Capitalization0.390.370.3373
Slightly volatile
Debt Equity Ratio0.650.620.5697
Slightly volatile
Quick Ratio0.540.571.093
Slightly volatile
Cash Ratio0.230.250.5167
Slightly volatile
Cash Conversion Cycle129145187
Very volatile
Operating Cash Flow Sales Ratio0.230.280.1937
Slightly volatile
Days Of Inventory Outstanding150260224
Slightly volatile
Days Of Sales Outstanding11571.0598.471
Slightly volatile
Cash Flow Coverage Ratios0.240.261.1211
Slightly volatile
Price To Book Ratio0.590.621.4916
Slightly volatile
Fixed Asset Turnover4.222.742.9739
Slightly volatile
Price Cash Flow Ratio3.814.0121.3831
Slightly volatile
Enterprise Value Multiple8.575.412.1559
Slightly volatile
Debt Ratio0.30.280.2509
Slightly volatile
Cash Flow To Debt Ratio0.240.261.1211
Slightly volatile
Price Sales Ratio0.920.971.9194
Slightly volatile
Asset Turnover0.450.330.3631
Slightly volatile
Gross Profit Margin0.570.620.6726
Pretty Stable
Price Fair Value0.590.621.4916
Slightly volatile

Takeda Pharmaceutical Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.7 T3.9 T3.8 T
Pretty Stable
Enterprise Value3.8 T6.5 T5.5 T
Slightly volatile

Takeda Fundamental Market Drivers

Forward Price Earnings23.0415
Cash And Short Term Investments553.7 B

Takeda Upcoming Events

1st of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Takeda Pharmaceutical Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Takeda Pharmaceutical income statement, its balance sheet, and the statement of cash flows. Takeda Pharmaceutical investors use historical funamental indicators, such as Takeda Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Takeda Pharmaceutical investors may use each financial statement separately, they are all related. The changes in Takeda Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Takeda Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Takeda Pharmaceutical Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Takeda Pharmaceutical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue709 B744.4 B
Total Revenue4.6 T4.9 T
Cost Of Revenue1.4 T1.5 T
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.47  0.37 
Research And Ddevelopement To Revenue 0.18  0.19 
Capex To Revenue(0.18)(0.17)
Revenue Per Share2.3 K2.5 K
Ebit Per Revenue 0.14  0.21 

Takeda Pharmaceutical Investors Sentiment

The influence of Takeda Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Takeda. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Takeda Pharmaceutical's public news can be used to forecast risks associated with an investment in Takeda. The trend in average sentiment can be used to explain how an investor holding Takeda can time the market purely based on public headlines and social activities around Takeda Pharmaceutical Co. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Takeda Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Takeda Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Takeda Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Takeda Pharmaceutical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Takeda Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Takeda Pharmaceutical's short interest history, or implied volatility extrapolated from Takeda Pharmaceutical options trading.

Currently Active Assets on Macroaxis

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.
Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for Takeda Stock analysis

When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.12)
Dividend Share
184
Earnings Share
0.36
Revenue Per Share
1.3 K
Quarterly Revenue Growth
0.013
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.